SCHEDULE: Renaissance Technologies Discloses Stake in Collegium Pharma

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a beneficial ownership of 4.53% in Collegium Pharmaceutical, Inc.

Summary

• Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have filed a Schedule 13G, indicating their beneficial ownership of Collegium Pharmaceutical, Inc. common stock.
• The total number of shares beneficially owned by these entities is 1,469,449.
• This represents 4.53% of the class of securities.
• Both entities share sole voting power and sole dispositive power over these shares.
• The filing is an amendment, with the event date requiring the filing being January 8, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a significant investment by a reputable firm, but provides no direct performance data for the company itself.

Positives

• Significant stake held by a well-known investment firm, potentially indicating confidence in the company's future.
• The filing is an amendment, suggesting ongoing management of the investment portfolio.

Negatives

• The filing does not contain specific financial performance data for Collegium Pharmaceutical, Inc., making it difficult to assess the company's current health from this document alone.

Risks

• The filing does not explicitly mention any risks associated with Collegium Pharmaceutical, Inc. or the investment itself.

Future Outlook

This filing does not contain forward-looking statements or guidance from Collegium Pharmaceutical, Inc. It solely reports the ownership stake of Renaissance Technologies.

Management Comments

• Certain funds managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a significant institutional investor like Renaissance Technologies often signals a substantial, non-controlling stake, typically held for investment purposes. This can be interpreted as a positive signal regarding the investor's view on the company's long-term prospects, though it does not imply active management or control.

Stakeholder Impact

• Shareholders: The filing may be viewed positively by some shareholders as it indicates confidence from a major investment firm, potentially influencing market perception.
• Management: The filing confirms a significant institutional investor's presence, which may lead to increased scrutiny or engagement from Renaissance Technologies.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Renaissance Technologies will continue to monitor its investment in Collegium Pharmaceutical, Inc.
• Further filings will be made if ownership levels change significantly.

Key Dates

Keywords

Schedule 13G, Renaissance Technologies, Collegium Pharmaceutical, beneficial ownership, investment, common stock, SEC filing